AR and prostate cancer: Interestingly, prostate cancer therapy with androgen receptors inhibitors such as enzalutamide, dramatically changes the expression of a pool of circRNAs in enzalutamide-resistant cells, opening new scenarios for understanding resistance mechanisms and offering novel opportunities for treating prostate cancer patients [200].